Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients

الملخص EN

Background.

The one-stage assay is the most common method to measure factor VIII activity (FVIII : C) in hemophilia A patients.

The chromogenic assay is another two-stage test involving purified coagulation factors followed by factor Xa-specific chromogenic substrate.

Aim.

This study aimed to assess the discrepancy and correlation between the chromogenic and one-stage assays in measuring FVIII : C levels in hemophilia patients receiving Extended Half-Life Elocta® as a recombinant extended half-life coagulation factor.

Methods.

We performed a study comparing the measurements of FVIII : C levels by the chromogenic versus the one-stage assays at different drug levels.

Data of FVIII : C levels, dosage, and the time interval from administration to measurement were retrieved from the hospital records.

The correlation, mean differences, and discrepancy between the two assays were calculated.

The linear regression analysis was used to predict the time interval till reaching 1% FVIII : C.

Results.

Fourteen patients with 56 samples were included in the study.

Of them, 13 patients were receiving Elocta® as a prophylactic, while one was receiving Elocta® on demand.

One-third of these samples showed a discrepancy between the chromogenic and one-stage assays.

The two assays were well correlated.

Mean differences were significant at the individual and the time interval level.

The time since the last Elocta® injection could significantly predict FVIII : C levels (β = 0.366, P<0.001).

Conclusion.

Our findings suggested a significant difference between both methods; the FVIII : C levels measured by the one-stage assay were less than those estimated by the chromogenic assay.

However, the measurements of FVIII levels by the two assays were well correlated but discrepant in one-third of the samples.

The levels of FVIII : C reach 1% after 5.4 days since the last Elocta® administration.